# **U** NOVARTIS

## A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Last Update: Jul 08, 2025

A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light Levels (SOSTOS) ClinicalTrials.gov Identifier: <u>NCT05090371</u> Novartis Reference Number:COMB157GUS09 <u>See if you Pre-qualify</u>

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

## **Study Description**

This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab. This is a multicenter, prospective study of up to 150 relapsing-remitting MS participants/ The study is looking to see if patients who have not had a relapse in the past year would benefit from switching to ofatumumab.

After giving consent, participants will have a 1 week screening/qualification period. If they qualify to continue, they will start a a six month run-in period during which lab samples will be collected. Patients that are relapsefree during the run-in period will continue into next period of the study in which they will be randomized to either of atumumab or continued therapy for the next 15 months. Every 3 out of 5 randomized participants will be selected to wear a digital study watch to collect physical activity, sleep, and vitals during this 15 month period. The study watch will be worn 24 hours a day, 7 days a week but can be removed during showers/bathing. At the end of the 15 month period, a study completion visit will be held.

The total study duration is 21 months plus 1 week for screening/qualification.

Condition Relapsing-Remitting Multiple Sclerosis Phase Phase4 Overall Status Recruiting Number of Participants 150 Start Date Mar 02, 2022 Completion Date Dec 31, 2026 Gender All Age(s) 18 Years - 50 Years (Adult)

## Interventions

Drug

## Disease modifying treatment (DMT)

Other DMT with approved label use for treatment which participants were on at least 6 months prior to Screening

Drug

### Ofatumumab

3 loading doses followed by administration every 4 weeks as per label

## **Eligibility Criteria**

Inclusion Criteria:

- \* Signed informed consent must be obtained prior to participation in the study.
- \* Age 18-45 years
- \* Diagnosis of RRMS per McDonald Criteria (2017)
- \* EDSS 0-5.5 (Inclusive)
- \* Able to obtain MRI and attend study visits at sites
- \* Willing to use wearable device as specified in the protocol
- \* Able to provide blood sample
- \* On a current DMT with approved label use for treatment of RRMS at least 6 months prior to Screening
- \* No relapse reported within 6 months prior to Screening
- \* Patients may enroll in the trial if they have subclinical disease activity as measured by MRI prior to enrollment. An absence of MRI activity is not exclusionary.

#### Exclusion Criteria:

- \* Primary progressive or secondary progressive phenotype
- \* Diseases other than multiple sclerosis responsible for the clinical or MRI presentation
- \* Use of experimental or investigational drugs for MS within 2 years from Screening
- \* Known sensitivity to gadolinium
- \* Central Nervous System (CNS) anomalies that are better accounted for by another disease process
- \* Known active malignancies
- \* Active chronic disease (or stable but treated with immune therapy) of the immune system other than MS

\* Active infections including systemic bacterial, viral (including COVID-19) or fungal infections, known to have AIDS or tested positive for HIV antibodies

- \* Neurological findings consistent with Progressive Multifocal Leukoencephalopathy (PML), or confirmed PML
- \* IgG or IgM levels below lower limit of normal (LLN) at Screening

#### Canada

#### **Novartis Investigative Site**

Recruiting

Granby,Quebec,J2g 1t7,Canada

#### **Novartis Investigative Site**

Recruiting

Levis,Quebec,G6w 0m5,Canada

#### **Novartis Investigative Site**

Recruiting

Saskatoon,Saskatchewan,S7k 0m7,Canada

#### **Novartis Investigative Site**

Recruiting

Edmonton, Alberta, T6g 2b7, Canada

#### **Novartis Investigative Site**

Recruiting

Vancouver, British Columbia, V6t 2a1, Canada

#### **Novartis Investigative Site**

Recruiting

Burnaby, British Columbia, V5g 2x6, Canada

#### **United States**

#### Palmetto Clinical Research

Recruiting

Summerville, South Carolina, 29485, United States

Robert Carlile

Phone: 843-851-7098

#### **Orlando Health Clinical Trials**

#### Recruiting

Orlando, Florida, 32806, United States

#### Tiffany Gilliard

Phone: <u>407-352-5434</u> Email: <u>Tiffany.gilliard@orlandohealth.com</u>

Amparo Gutierrez

#### Kootenai Health

Recruiting

Coeur d'Alene, Idaho, 83815, United States

Phone: 208-625-5273

Nina Bozinov

#### **Covenant Medical Group**

Recruiting

Lubbock, Texas, 79410, United States

Bhupesh Dihenia

Phone: 806-722-3500

#### Homestead Assoc In Research Inc

Recruiting

Homestead, Florida, 33033, United States

Phone: 305-246-0873

Angel Carrasco

#### Aurora BayCare Medical Center

Recruiting

Green Bay, Wisconsin, 54311, United States

James Napier

Phone: 920-288-8100

#### Arizona Neuroscience Research LLC

#### Recruiting

Phoenix, Arizona, 85032, United States

Leslie Zuniga

Phone: 480-210-8723

#### **University Of NC At Chapel Hill**

Recruiting

Chapel Hill, North Carolina, 27599 9500, United States

Phone: 919-945-4752

Irena Dujmovic Basuroski

#### **Reliant Medical Group**

#### Recruiting

Worcester, Massachusetts, 01608, United States

Gary Keilson

Candace Leblanc

Phone: <u>508-368-3168</u> Email: <u>candace.leblanc@reliantmedicalgroup.org</u>

#### North Central Neurology Associates PC

Recruiting

Cullman, Alabama, 35058, United States

Phone: 256-739-1210

Christopher LaGanke

#### **Neuro Mind Clinical Trials Ltd Co**

Recruiting

Katy, Texas, 77449, United States

Jontel Pierce

#### Sibyl Wray MD Neurology PC

Recruiting

Knoxville, Tennessee, 37922, United States

Phone: 865-218-6222

Sibyl Wray

#### **Henry Ford Hospital**

Recruiting

Detroit, Michigan, 48202 2689, United States

Phone: 313-556-8186

Mirela Cerghet

#### West Texas Cancer Center

Recruiting

Odessa, Texas, 79761, United States

Phone: 432-368-2138

Cathy Sabouni

#### Medical College of Wisconsin

Recruiting

Milwaukee, Wisconsin, 53226, United States

Phone: 414-955-0693

Ahmed Obeidat

#### University of California at Los Angeles

Recruiting

Torrance, California, 90509-2004, United States

Phone: <u>949-547-6875</u>

Bijal Mehta

#### Jersey Shore University Medical Ctr

Recruiting

Neptune, New Jersey, 07753, United States

Phone: 732-776-4782

#### **Evergreen Health Multiple Sclerosis Center**

Recruiting

Kirkland, Washington, 98034, United States

Phone: 425-899-5385

Jason Poon

#### **Neuro Medial Clinic of Central Louisiana**

Recruiting

Alexandria, Louisiana, 71301, United States

Phone: 318-769-2862

Ariel Antezana-Antezana

#### **Emerald Coast Neurology**

Recruiting

Pensacola, Florida, 32514, United States

Phone: 850-438-1136

David Bear

#### **Velocity Clinical Research**

Recruiting

Raleigh, North Carolina, 27607, United States

Phone: <u>919-719-8826</u>

Casey Farin

#### Neurology of Central FL Res Ctr

Recruiting

Altamonte Springs, Florida, 32714, United States

Phone: <u>407-790-4990</u>

#### Alicia Cabrera

#### **Radiant Research Chandler**

#### Recruiting

Chandler, Arizona, 85224, United States

Osman Salim

#### **Memorial Healthcare**

Recruiting

Owosso, Michigan, 48867, United States

Jeanie Lynn Cote

#### **Tranquil Clinical Research**

Recruiting

Webster, Texas, 77598, United States

#### Amber Christian

Phone: <u>713-906-6316</u> Email: <u>amberc@tranquilityresearch.com</u>

#### Razi Rashid

#### **Neurology Associates PA**

Recruiting

Maitland, Florida, 32751, United States

Phone: <u>+1 407 647 5996 #7</u>

William David Honeycutt

#### **Piedmont HealthCare**

Recruiting

Charlotte,North Carolina,28210,United States

Phone: 704-664-8060

Matthew Carraro

#### **Swedish Medical Center**

#### Recruiting

#### Seattle, Washington, 98122-4379, United States

Phone: 206-320-2200

Pavle Repovic

#### International Neurorehab Institute

Recruiting

Lutherville, Maryland, 21093, United States

Phone: 410-828-4629

Daniel Becker

#### University of Mississippi Medical Center

Recruiting

Jackson, Mississippi, 39216-4505, United States

Phone: 888-815-2005

Mary Willis

#### **University Of South Florida**

Recruiting

Tampa, Florida, 33612, United States

Phone: 813-974-6378

John Ciotti

#### **Clinical Trial Network**

Recruiting

Houston, Texas, 77074, United States

Djamchid Lotfi

Santiago Rios

Email: srios@ctntexas.com

#### Alabama Neurology Associates PC

Recruiting

Birmingham, Alabama, 35209, United States

Emily Sherill Riser

#### S And D Clinical Research

Recruiting

Cape Coral, Florida, 33904, United States

Phone: 239-722-9733

Jorge Diaz

#### Sentara Neuroscience Institute

Recruiting

Virginia Beach, Virginia, 23456, United States

Phone: 757-507-0642

Michelle Betz-Kuczma

#### **SUNY Upstate Medical Center**

Recruiting

Syracuse, New York, 13210, United States

Corey McGraw

## **Worldwide Contacts**

If the location of your choosing does not feature any contact detail, please reach out using the information below.

#### **Novartis Pharmaceuticals**

Phone: <u>+41613241111</u> Email:

#### **Novartis Pharmaceuticals**

Phone: <u>1-888-669-6682</u> Email: <u>novartis.email@novartis.com</u>

Source URL: https://prod1.novartis.com/clinicaltrials/study/nct05090371

#### List of links present in page

- 1. https://clinicaltrials.gov/ct2/show/NCT05090371
- 2. #trial-eligibility
- 3. tel:843-851-7098
- 4. tel:407-352-5434
- 5. mailto:Tiffany.gilliard@orlandohealth.com
- 6. tel:208-625-5273
- 7. tel:806-722-3500

- 8. tel:305-246-0873 9. tel:920-288-8100 10. tel:480-210-8723 11. tel:919-945-4752 12. tel:508-368-3168 13. mailto:candace.leblanc@reliantmedicalgroup.org 14. tel:256-739-1210 15. tel:865-218-6222 16. tel:313-556-8186 17. tel:432-368-2138 18. tel:414-955-0693 19. tel:949-547-6875 20. tel:732-776-4782 21. tel:425-899-5385 22. tel:318-769-2862 23. tel:850-438-1136 24. tel:919-719-8826 25. tel:407-790-4990 26. tel:713-906-6316 27. mailto:amberc@tranquilityresearch.com 28. tel:+1 407 647 5996 #7 29. tel:704-664-8060 30. tel:206-320-2200 31. tel:410-828-4629 32. tel:888-815-2005 33. tel:813-974-6378 34. mailto:srios@ctntexas.com 35. tel:239-722-9733 36. tel:757-507-0642 37. tel:+41613241111
- 38. mailto:
- 39. tel:1-888-669-6682
- 40. mailto:novartis.email@novartis.com